SIETES :: 92005 citas

Resultados de la búsqueda por USA REFINAR BÚSQUEDA

1.

Prasad V, Mailan S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med 2017:1. [Ref.ID 102051]

2.

Anónimo. Insys Therapeutics faked cancer diagnoses to sell more of its opioid medication, senator says. DIA Daily 2017:11. [Ref.ID 102048]

3.

Silverman E. Allergan’s deal with the Mohawks raises troubling questions about the future of generics. STAT 2017:1. [Ref.ID 102047]

4.

Anónimo. Insys ignored warnings, manipulated marketing of fentanyl, investigation suggests. DIA Daily 2017:1. [Ref.ID 102046]

5.

Anónimo. Novo Nordisk to pay $58.7 million to settle US probe over diabetes drug liraglutide. DIA Daily 2017:1. [Ref.ID 102045]

6.

Anónimo. FDA Approves CAR-T therapy for treatment of childhood leukemia. DIA Daily 2017:1. [Ref.ID 102036]

7.

Anónimo. FDA rules Novo Nordisk’s diabetes drug reduces risk of heart attack, stroke, cardiovascular death. DIA Daily 2017:2. [Ref.ID 102035]

8.

Cruz ML, Xu J, Kashoki M, Lurie P. Publication and reporting of the results of postmarket studies for drugs required by the US Food and Drug Administration, 2009 to 2013. JAMA Intern Med 2017;177:1207-10. [Ref.ID 102016]

9.

Becker WC, Fiellin DA. Limited evidence, faulty reasoning, and potential for a global opioid crisis. BMJ 2017;358:j3115. [Ref.ID 102015]

10.

Anónimo. Corticoïdes en cure courte: fractures, thromboses, infections. Prescrire 2017;37:507. [Ref.ID 102006]

11.

Ma GK, Brensinger CM, Wu Q, Lewis JD. Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study. Ann Intern Med 2017;167:152-8. [Ref.ID 101991]

12.

Rosenberg HG, Shnier A. Regulatory data are hidden in plain sight. BMJ 2017;358:j3437. [Ref.ID 101980]

13.

Fralick M, Avorn J, Kesselheim AS. The price of crossing the border for medications. N Engl J Med 2017;377:311-3. [Ref.ID 101925]

14.

Ringel MS, Choy MK. Opinion: A new wave of pharma mergers could put innovative drugs in the pipeline. STAT 2017:2. [Ref.ID 101920]

15.

Anónimo. PhRMA, BIO increased spending on federal lobbying. DIA Daily 2017:1. [Ref.ID 101918]

16.

Hodges NL, Spiller HA, Casavant MJ, Chounthirath T, Smith GA. Non-health care facility medication errors resulting in serious medical outcomes. Clinical Toxicology 2017:1-8. [Ref.ID 101917]

17.

Anónimo. FDA approves HCV drug for patients who fail to respond to prior treatments that inhibit NS5A. DIA Daily 2017:1. [Ref.ID 101910]

18.

Anónimo. FDA approves guselkumab for treatment of plaque psoriasis. DIA Daily 2017:2. [Ref.ID 101909]

19.

Patorno E, Glynn RJ, Levin R, Lee MP, Huybrechts KF. Benzodiazepines and risk of all cause mortality in adults: cohort study. BMJ 2017;358:j2941. [Ref.ID 101907]

20.

Guy Jr GP, Zhang K, Bohm MK, Lewis B, Young R, Murphy LB, Dowell D. Vital Signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66:697-704. [Ref.ID 101665]